MedCity News April 13, 2021
Chance Scott

No matter if Democrats or Republicans are running the show in Washington, here are three solid bets for pharma companies to plan for in the changing drug-pricing landscape

Pounded by both sides of the political aisle, pharmaceutical companies know what it feels like to be whipsawed by opposite ends of the American reimbursement system.

Two weeks after the November election, President Trump announced a new model for federal drug pricing that was supposed to begin in January. Shortly after taking office, though, President Biden halted, if not canceled, many of those changes for at least a year. 

Though some pharma companies saw the Biden blockage as a cause for celebration — a kind of stay of execution — I believe...

Today's Sponsors

Teladoc Health

Today's Sponsors

Canton & Company

Today's Sponsor


Topics: Biotechnology, Govt Agencies, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending
NIH to test repurposing up to 7 drugs to treat COVID-19 symptoms at home
Decentralized Clinical Trials: Surviving & Thriving in the Clinical Research World of COVID-19
The FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar
To Improve Competition In Generic Drug Markets, The FDA Should Discount User Fees For Small Players
Designing better antibody drugs with artificial intelligence